Needham & Company Reiterates a 'Buy' on Alnylam Pharmaceuticals (ALNY); Accelerated ALN-TTR Development May Sustain Stock Momentum in 2012
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $228.65 +0.67%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Alnylam Pharmaceuticals (NASDAQ: ALNY) price target of $16.00.
Analyst, Alan Carr, said, "Alnylam management reviewed 4Q11 in a quarterly conference call yesterday after market close. With the January 2012 restructuring, the company is placing greater emphasis on development of ALN-TTR-02 (transthyretin amyloidosis) and ALN-APC (hemophilia). ALN-TTR-02 may be ready for a pivotal Phase 3 trial in 2013. ALN-APC is expected to enter the clinic in 1H13."
"The stock has done well over the course of 2H11 and into 2012, in concert with positive developments from the company pipeline. We continue to believe the stock is undervalued (~$300M EV). Recent ALN-PCS and ALN-TTR proof of concept data have broad positive implications for RNAi therapy as a whole."
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $13.05 yesterday.
Analyst, Alan Carr, said, "Alnylam management reviewed 4Q11 in a quarterly conference call yesterday after market close. With the January 2012 restructuring, the company is placing greater emphasis on development of ALN-TTR-02 (transthyretin amyloidosis) and ALN-APC (hemophilia). ALN-TTR-02 may be ready for a pivotal Phase 3 trial in 2013. ALN-APC is expected to enter the clinic in 1H13."
"The stock has done well over the course of 2H11 and into 2012, in concert with positive developments from the company pipeline. We continue to believe the stock is undervalued (~$300M EV). Recent ALN-PCS and ALN-TTR proof of concept data have broad positive implications for RNAi therapy as a whole."
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $13.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings
- Needham Reiterates Buy Rating on Digimarc (DMRC)
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
